Show simple item record

AuthorPoomakkoth, Noufira
AuthorIssa, Aya
AuthorAbdulrahman, Nabeel
AuthorAbdelaziz, Somaia Gamal
AuthorMraiche, Fatima
Available date2016-11-02T06:42:58Z
Publication Date2016-01-14
Publication NameJournal of Translational Medicineen_US
Identifierhttp://dx.doi.org/10.1186/s12967-016-0768-1
CitationPoomakkoth N, Issa A, Abdulrahman N, Abdelaziz SG, Mraiche F. p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer. Journal of Translational Medicine. 2016;14:14.
URIhttp://hdl.handle.net/10576/4951
AbstractA global survey of cancer has shown that lung cancer is the most common cause of the new cancer cases and cancer deaths in men worldwide. The mortality from lung cancer is more than the combined mortality from breast, prostate and colorectal cancers. The two major histological types of lung cancer are non-small cell lung cancer (NSCLC) accounting for about 85 % of cases and small cell lung cancer accounting for 15 % of cases. NSCLC, the more prevalent form of lung cancer, is often diagnosed at an advanced stage and has a very poor prognosis. Many factors have been shown to contribute to the development of lung cancer in humans including tobacco smoking, exposure to environmental carcinogens (asbestos, or radon) and genetic factors. Despite the advances in treatment, lung cancer remains one of the leading causes of cancer death worldwide. Interestingly, the overall 5 year survival from lung cancer has not changed appreciably in the past 25 years. For this reason, novel and more effective treatments and strategies for NSCLC are critically needed. p90 ribosomal S6 kinase (RSK), a serine threonine kinase that lies downstream of the Ras–MAPK (mitogen activated protein kinase) cascade, has been demonstrated to be involved in the regulation of cell proliferation in various malignancies through indirect (e.g., modulation of transcription factors) or direct effects on the cell-cycle machinery. Increased expression of RSK has been demonstrated in various cancers, including lung cancer. This review focuses on the role of RSK in lung cancer and its potential therapeutic application.
SponsorQatar University Internal Grant (QU UG2013/2014).
Languageen
PublisherBioMed Central
Subjectp90 ribosomal S6 kinase
SubjectLung adenocarcinomas
SubjectMitogen activated protein kinases
SubjectEpidermal growth factor
Titlep90 ribosomal S6 kinase: a potential therapeutic target in lung cancer
TypeArticle
Issue Number14
Volume Number14
dc.identifier.essn 1479-5876


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record